UNIVERSITY OF MIAMI

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1925-01-01

Employees: 10K

Market Cap: -

Website: https://continue.miami.edu/packagedetail.aspx

Clinical Trials

Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

Phase 4

Completed

Conditions: End-Stage Renal Disease
Living Donors

Interventions: Drug: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab

First Posted Date: 2010-01-12

Last Posted Date: 2010-01-12

Lead Sponsor: University of Miami

Target Recruit Count: 38

Registration Number: NCT01046955

Locations: 🇺🇸
University of Miami Jackson Memorial Hospital, Miami, Florida, United States

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

Completed

Conditions: Glaucoma

Interventions: Drug: latanoprost 0.005%
Drug: Placebo

First Posted Date: 2010-01-05

Last Posted Date: 2014-03-28

Lead Sponsor: University of Miami

Target Recruit Count: 82

Registration Number: NCT01042665

Locations: 🇺🇸
University of Miami Bascom Palmer Eye Institute, Palm Beach Gardens, Florida, United States

Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus

Phase 4

Withdrawn

Conditions: Living Donor Kidney Transplants Patients

Interventions: Drug: Tacrolimus, Myfortic and Sirolimus

First Posted Date: 2009-12-24

Last Posted Date: 2024-06-03

Lead Sponsor: University of Miami

Registration Number: NCT01038505

Familias Unidas: Preventing Substance Abuse in Hispanic Youth

Phase 2

Completed

Conditions: Sexual Behavior
Prevention
Substance Use
Family Function

Interventions: Behavioral: Familias Unidas

First Posted Date: 2009-12-23

Last Posted Date: 2015-06-03

Lead Sponsor: University of Miami

Target Recruit Count: 746

Registration Number: NCT01038206

Locations: 🇺🇸
Center for Family Studies and Miami-Dade County Public Schools, Miami, Florida, United States

Nebivolol Versus Metoprolol: Sodium Sensitivity

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: nebivolol
Drug: Metoprolol

First Posted Date: 2009-10-08

Last Posted Date: 2017-06-08

Lead Sponsor: University of Miami

Target Recruit Count: 24

Registration Number: NCT00992056

Locations: 🇺🇸
Division of Clinical Pharmacology Clinical Pharmacology Research Unit (CPRU) 1500 NW 12th Ave 15-West., Miami, Florida, United States

Use of Hextend in Trauma

Completed

Conditions: Trauma

Interventions: Drug: Hextend

First Posted Date: 2009-09-24

Last Posted Date: 2017-06-14

Lead Sponsor: University of Miami

Target Recruit Count: 1714

Registration Number: NCT00983281

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

Phase 1

Terminated

Conditions: Cholangiocarcinoma
Biliary Tract Cancer
Gallbladder Cancer

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Sorafenib

First Posted Date: 2009-08-10

Last Posted Date: 2018-01-03

Lead Sponsor: University of Miami

Target Recruit Count: 9

Registration Number: NCT00955721

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors

Not Applicable

Completed

Conditions: Acute Lymphoblastic Leukemia
Lymphoma
Central Nervous System Tumors

Interventions: Behavioral: Annual Intervention Group
Behavioral: Quarterly Monitoring of IEP

First Posted Date: 2009-07-24

Last Posted Date: 2012-03-08

Lead Sponsor: University of Miami

Target Recruit Count: 62

Registration Number: NCT00945828

Locations: 🇺🇸
Mailman Center for Child Development University of Miami Miller School of Medicine, Miami, Florida, United States

Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV

Not Applicable

Completed

Conditions: Cardiovascular Diseases
HIV
Acquired Immunodeficiency Syndrome

Interventions: Behavioral: Control Group
Behavioral: Exercise Program

First Posted Date: 2009-05-25

Last Posted Date: 2015-12-07

Lead Sponsor: University of Miami

Target Recruit Count: 16

Registration Number: NCT00908284

Locations: 🇺🇸
University of Miami, Department of Pediatrics, Division of Clinical Research, Batchelor Children's Research Institute, Miami, Florida, United States

Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: gemcitabine hydrochloride
Drug: vinorelbine ditartrate

First Posted Date: 2009-04-15

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Registration Number: NCT00881387

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy